Publications by authors named "Matthew F Peters"

Claim this Profile
D
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome.
Avipsa Ghosh, Afshan Ahmed, Konstantina Amoiradaki, Amber Y S Balazs, Bernard Barlaam, Matthew F Peters

J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs.
David G Belair, Richard J Visconti, Miyoun Hong, Mathieu Marella, Matthew F Peters

Toxicol In Vitro· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems.
Matthew F Peters, Allison L Choy, Carmen Pin, Derek J Leishman, Annie Moisan

Lab Chip· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches.
Sarah D Lamore, Rebecca A Kohnken, Matthew F Peters, Kyle L Kolaja

Chem Res Toxicol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea.
Matthew F Peters, Tim Landry, Carmen Pin, Kim Maratea, Cortni Dick

Toxicol Sci· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconvoluting Kinase Inhibitor Induced Cardiotoxicity.
Sarah D Lamore, Ernst Ahlberg, Scott Boyer, Michelle L Lamb, Maria P Hortigon-Vinagre, Matthew F Peters

Toxicol Sci· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.
Matthew F Peters, Sarah D Lamore, Liang Guo, Clay W Scott, Kyle L Kolaja

Cardiovasc Toxicol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
Clay W Scott, Xiaoyu Zhang, Najah Abi-Gerges, Sarah D Lamore, Yama A Abassi, Matthew F Peters

Toxicol Sci· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.
Sarah D Lamore, Harriet W Kamendi, Clay W Scott, Yvonne P Dragan, Matthew F Peters

Toxicol Sci· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.
Clay W Scott, Matthew F Peters, Yvonne P Dragan

Toxicol Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Matthew F Peters, Clay W Scott, Rafal Ochalski, Yvonne P Dragan

Assay Drug Dev Technol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity.
Matthew F Peters, Anna Zacco, John Gordon, Carla M Maciag, Linda C Litwin

Eur J Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.
Todd A Brugel, Reed W Smith, Michael Balestra, Christopher Becker, Thalia Daniels, Matthew F Peters

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Label-free whole-cell assays: expanding the scope of GPCR screening.
Clay W Scott, Matthew F Peters

Drug Discov Today· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.
Todd A Brugel, Reed W Smith, Michael Balestra, Christopher Becker, Thalia Daniels, Matthew F Peters

Bioorg Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing label-free biosensors for pharmacological screening with cell-based functional assays.
Matthew F Peters, François Vaillancourt, Madeleine Heroux, Manon Valiquette, Clay W Scott

Assay Drug Dev Technol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity.
Matthew F Peters, Clay W Scott

J Biomol Screen· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs.
Matthew F Peters, Katharine S Knappenberger, Deidre Wilkins, Linda A Sygowski, Lois Ann Lazor

J Biomol Screen· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation.
Shuichi Igarashi, Hokuto Morita, Kyla M Bennett, Yuji Tanaka, Simone Engelender, Matthew F Peters

Neuroreport· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis